FLT3‐ITD targeted therapy has confirmed FLT3‐ITD mutations as leukemic drivers as well as possible therapeutic targets both in model systems [21, 22] and in AML patients [23, 24, 25]. This evidence concerns the gene FLT3 and acute myeloid leukemia.